Verastem (VSTM) Target Price Reduced to $14 with 211% Upside
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowRBC Capital maintained its Outperform rating on Verastem Inc. (NASDAQ: VSTM) and reduced the target price from $15 to $14, suggesting an upside potential of over 211%. This decision aligns with the firm's broader earnings preview for the biotech sector, following a rally in June. Verastem recently reported positive preliminary results from its Phase 1/2 trial for VS-7375, targeting late-stage KRAS G12D-mutated tumors. This information is significant for investors as it highlights the company's potential amid a favorable sentiment in the biotech sector.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
